258 filings
Page 7 of 13
8-K
gz42fvf5s 0al2
8 Jan 18
Regulation FD Disclosure
12:00am
8-K
846pb5
3 Jan 18
Departure of Directors or Certain Officers
12:00am
8-K
zmmu7xicd
18 Dec 17
Other Events
12:00am
CT ORDER
fpbp4lu 0yg9y7wd1v
28 Nov 17
Confidential treatment order
12:00am
8-K
7xng3gb
15 Nov 17
Departure of Directors or Certain Officers
12:00am
8-K
3pnd9uk6 zotq
7 Nov 17
Acceleron Pharma Reports Third Quarter 2017 Operational and Financial Results
12:00am
8-K
kyz iyub3e
25 Sep 17
Other Events
12:00am
424B2
4b9fj7ga18w sso3s46
21 Sep 17
Prospectus for primary offering
12:00am
S-3ASR
b4w3ac4t3sn81
19 Sep 17
Automatic shelf registration
12:00am
8-K
6hy24y4hx 0j
19 Sep 17
Entry into a Material Definitive Agreement
12:00am
424B5
2x1yrh4w xmb
19 Sep 17
Prospectus supplement for primary offering
12:00am
8-K
quswzus5iy4
3 Aug 17
Acceleron Pharma Reports Second Quarter 2017 Operational and Financial Results
12:00am
S-8
mxklv
3 Aug 17
Registration of securities for employees
12:00am
8-K
8hl5br22jvud7af
19 Jul 17
Entry into a Material Definitive Agreement
12:00am
8-K
e1vnet
30 Jun 17
Other Events
12:00am
8-K
npvqyyrw500
15 Jun 17
Acceleron Announces Top-Line Results from DART Phase 2 Study of Dalantercept in Advanced Renal Cell Carcinoma
12:00am
8-K
da6eug88yly0
6 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
uksx0ckqp52q469912xs
10 May 17
Luspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes
12:00am